By 2013, Merck & Co wants the leading emerging markets to account for a quarter of its revenues, representing a 50% hike from 2010. Dr Merv Turner, Merck's chief strategy officer, explains to Mike Ward how the company, currently ranked fifth in emerging markets, plans to hit such an ambitious target.

Read more

Click on the chart to zoom

India's position as a hotbed for industry-sponsored clinical trials is growing in leaps and bounds. The following charts, illustrating Phase II-III trials initiated in the country in 2010, paint a picture of one major emerging market's clinical trials landscape, including top therapy areas, most active trial sponsors and most popular indications. Data provided by TrialTrove.
Read more

One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in the country, where it expects to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic players, Abbott isn't about to get complacent, Michael Warmuth, head of the company's Established Products Division, tells Pete Chan.
Read more

Visions of 2020
5 May 2011
How might the Indian pharmaceutical landscape look in a decade's time?

Indian firms lead para IV charge, lock in key first-to-file opportunities
31 May 2011
Indian companies are starting to dominate the genericisation of blockbuster drugs.

Indian drug makers seek government protection from cheap Chinese APIs
3 June 2011
Indian firms complain that "unhealthy competition" from China is eroding their edge in API production.